Product
Adriamycin
3 clinical trials
3 indications
Indication
CancerIndication
Multiple MyelomaIndication
Soft Tissue SarcomaClinical trial
Multi-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-antigen Autologous Immune Cell Injection (MASCT-I) in Patients With Advanced Solid Tumor, and to Preliminarily Evaluate the Anti-tumor Efficacy of MASCT-I Alone, in Combination With Chemical Drugs, and in Combination With PD1 AntibodyStatus: Recruiting, Estimated PCD: 2023-07-01
Clinical trial
A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for MaintenanceStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
An Open, Multi-center, Randomized, Phase II Study of Adriamycin and Ifosfamide Combined With Sintilimab in the Treatment of Advanced or Unresectable Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-12-30